The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2021 | Changing treatment approaches for transplant-ineligible myeloma: DRd, BiTEs and CAR-T
Thomas Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses the optimal treatment regimen for patients with transplant-ineligible multiple myeloma. The MAIA trial (NCT02252172) has provided strong supportive evidence for the use of daratumumab-lenalidomide-dexamethasone (DRd) as induction therapy. Patients receiving this triplet combination have shown high rates of deep and durable responses. Prof. Martin goes on to discuss the future role of novel therapeutics, outlining how bispecific T-cell engagers (BiTEs) and CAR T-cells could be beneficially incorporated into the treatment plan for these patients. This interview took place during the 7th World Congress on Controversies in Multiple Myeloma (COMy), 2021.
